Get the latest news, insights, and market updates on EWTX (Edgewise Therapeutics, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on January 30, 2025, Edgewise granted inducement stock options to purchase a total of 198,250 shares of Edgewise's common stock to 7 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity In Feb 2, 2026 - $EWTX
Edgewise Therapeutics, Inc. (EWTX) Outlines Priorities For 2026
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is among the 14 best booming stocks to buy right now. The stock is surging and has gained over 57% in the last three months, as of the close on January 12. Shares closed 3% higher on Tuesday, January 13, after the company provided a corporate update and outlined its priorities […] Jan 15, 2026 - $EWTX
Why Edgewise Therapeutics (EWTX) Is Up 8.8% After Mapping Its 2026 Rare-Disease Pipeline Priorities – And What's Next
At the 44th Annual J.P. Morgan Healthcare Conference in early January 2026, Edgewise Therapeutics outlined its 2026 clinical priorities, including completing the GRAND CANYON pivotal cohort for Becker muscular dystrophy, progressing Duchenne and hypertrophic cardiomyopathy programs, and preparing a potential New Drug Application for sevasemten in 2027. An interesting aspect of the update is Edgewise’s attempt to build a multi-asset rare disease and cardiovascular portfolio, with sevasemten,... Jan 14, 2026 - $EWTX
A Look At Edgewise Therapeutics (EWTX) Valuation After J P Morgan Clinical Pipeline Update
Edgewise Therapeutics (EWTX) drew fresh attention after its J.P. Morgan Healthcare Conference update, where management detailed timelines for key 2026 milestones and potential regulatory steps across Becker muscular dystrophy and hypertrophic cardiomyopathy programs. See our latest analysis for Edgewise Therapeutics. The J.P. Morgan update comes after a strong 90 day share price return of 59.73%, alongside a more mixed picture that includes a 1 year total shareholder return decline of 9.34%... Jan 14, 2026 - $EWTX
Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided updates on the Company's clinical programs and highlighted major milestones for 2026. Edgewise Chief Executive Officer, Kevin Koch, Ph.D., will present these updates today at the J.P. Morgan 2026 Healthcare Conference. Jan 13, 2026 - $EWTX
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on December 31, 2025, Edgewise granted inducement stock options to purchase a total of 119,250 shares of Edgewise's common stock to 4 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity I Jan 5, 2026 - $EWTX
Edgewise Therapeutics (EWTX): Assessing Valuation After an 80% Three-Month Surge in the Share Price
Edgewise Therapeutics (EWTX) has quietly put up a strong run lately, with the stock climbing about 26% in a day and more than 80% over the past 3 months. See our latest analysis for Edgewise Therapeutics. The latest surge takes Edgewise Therapeutics to a share price of $27.29 and caps a powerful stretch, with short term share price momentum now catching up to its strong three year total shareholder return of over 230 percent. If this kind of momentum has your attention, it could be a good... Dec 25, 2025 - $EWTX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple